Good points that should make Brilacidin more attractive to any potential partners. I don't see another trial starting up for a new indication unless it is being conducted by a partner.
In Reply to 'mdphd2008'
If B-UP is found to be successful, another potential avenue of exploration can be its use for GI ulcers in the upper GI tract based on its anti-inflammatory and biofilm properties.
Carafate and/or sucralfate are currently one of the medications that I have seen to be quite effective in both hospital and outpatient settings both to prevent and/or treat gastric and duodenal ulcers.
Similarly to carafate, benefits may include low systemic absorption, excellent safety profile, and easy administration.
Furthermore, a potential phase 2 study should be relatively quick and easy to perform with an oral liquid formulation because the incidence of acid reflux and ulcers is extremely high in the general population (recruitment should not be an issue).
Also, an upper endoscopy to evaluate ulcers is an extremely quick procedure that does not require an extensive preparation for patients in advance (unlike colonoscopy), therefore, patient compliance should be high.
News 
Market Data 
Discover 
